Course Provider

COMPASS Pathways

COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.

ProfessionalHybridPremiumPsychedelic-assisted therapy trainingContinuing educationAcademic programmeLicensed cliniciansResearchersOther

Blossom’s read

COMPASS Pathways is best understood as a serious clinical-development company rather than a broad public training school. Its therapist programme appears to have been built for regulated trial delivery and commercial readiness, with a notable evidence-based lineage and input from established academics and clinicians in psychology, psychiatry and psychedelic research. In the field, that gives it credibility and structure, but also means it is most relevant to professionals operating in formal healthcare or research settings rather than to general interest learners.

Who COMPASS Pathways is for

Best suited to licensed clinicians and clinical-research staff who are involved, or expect to be involved, in psilocybin-assisted therapy delivery within regulated settings. It is less obviously aimed at the curious public or at standalone facilitators outside medical systems.

Prerequisites

The materials support that therapists are employed by clinical trial sites and that the programme is for healthcare professionals working in psilocybin therapy. Specific licensure or entry requirements are not clearly stated in the sources reviewed.

Accreditation & recognition

Compass says the therapist training programme was published in a peer-reviewed paper in Frontiers in Psychiatry, and its materials describe it as designed by experts and approved by the FDA for research purposes. I did not find clear evidence of formal third-party accreditation, CME, or CE credit for the programme in the sources reviewed.

Cost

No public tuition pricing was found. For the research context, Compass states it provides cGMP COMP360 psilocybin to researchers free of charge, while researchers cover packaging and shipping. That appears separate from any therapist training cost, which was not disclosed.

What you walk away with

Learners appear to gain a structured competency framework for supporting preparation, dosing and integration sessions in COMPASS-sponsored psilocybin research, with mentoring and professional development. The practical outcome is readiness to work on clinical trials or, more broadly, within Compass-aligned psilocybin care pathways.

Linked Courses

3

Active Listings

1

Primary Formats

Hybrid, Self-paced

Provider Focus Areas

Psilocybin Therapy (2)Clinical & Medical (2)Research & Science (2)

Courses from COMPASS Pathways

Programs linked directly to this provider in the Blossom course dataset.

Similar course providers

Reference points selected from shared training modalities, learner audience, level, delivery format, pricing, and location.

Drug Science
  • Strong match: 3 shared modalities
  • Strong match: 3 shared learner audiences
  • Also shares: professional level
  • Also shares: hybrid delivery
Experiential Training Institute
  • Strong match: 2 shared modalities
  • Strong match: 2 shared learner audiences
  • Also shares: professional level
  • Also shares: hybrid delivery
MIND Foundation
  • Strong match: 3 shared modalities
  • Strong match: 3 shared learner audiences
  • Also shares: professional level
  • Also shares: hybrid delivery
OPEN Foundation
  • Strong match: 3 shared modalities
  • Strong match: 3 shared learner audiences
  • Also shares: professional level
  • Also shares: hybrid delivery

Psychedelics Courses

A focused course directory powered by the current Blossom dataset, with full course profiles, provider pages, and category browsing for psychedelic education.